- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02673229
Comparison of Collagenase Santyl Ointment With Antibiotic Ointment in the Outpatient Care of Minor Partial Thickness Burns
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subjects who have minor, second degree burns may be enrolled in this study. Subjects will receive either Santyl ointment or bacitracin ointment to apply to the burn until it heals. Bandages will be used to keep the burn covered while it heals. Second degree burns generally leave a scar. Once the burn heals, lotion and an appropriate bandage will be used to try to minimize the appearance of a scar.
The study hypothesis is that burns treated with Santyl will have a better scar appearance than burns treated with bacitracin.
Subjects enrolled in this study will make once a week visits to the University of Kansas Medical Center outpatient burn clinic until the burn heals. The burn will be assessed for healing at these visits. Once healed, visits to the clinic will be at 60 & 180 days, up to 6 months. At these visits, the appearance of the scar will be evaluated.
This study was originally funded by Smith and Nephew, but Smith and Nephew is no longer providing support for the study.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Jessica Reynolds, BSN
- Phone Number: 913-588-0044
- Email: jreynolds11@kumc.edu
Study Locations
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- Recruiting
- University of Kansas Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provide written informed consent, which will consist of reading, signing, and dating the informed consent document after the Investigator, sub-Investigator or other designated study staff member has explained the study procedures, risks, and contact information. For subjects not able to provide informed consent (e.g., minors), a parent or legally authorized representative must provide consent. Assent must be provided as required by the Institutional Review Board (IRB).
Have one or more acute burns which:
- are thermal, chemical or electrical in etiology
- in aggregate cover <10% total body surface area (TBSA)
- are each equal to or less than 72 hrs old
- are each no more than deep partial thickness (2nd degree)
- are not visibly infected
- Able to take in oral fluids.
- Able to comply with the requirement for daily dressing changes, or have a caretaker who is able to comply.
- Willing to make all required study visits.
Exclusion Criteria:
- Contraindications or hypersensitivity to the use of the test article or their components (e.g., known hypersensitivity to bacitracin).
- Embedded foreign bodies in the burn wound which cannot be immediately removed.
- The burned tissue includes or is within 1 cm of the eye or genitalia.
- Severe perioral burns.
- Airway involvement or aspiration of hot liquids.
- Suspicion of physical abuse.
- Burn wound requires a skin graft.
- Outpatient management of the burn wound is not appropriate.
- Participation in another investigational clinical study within thirty (30) days of the Screening Visit.
- The Investigator may declare any subject ineligible for a valid medical reason. Current or recent (< 6 months) history of severe, unstable, or uncontrolled neurological, cardiovascular, gastrointestinal, hematological, hepatic, and/or renal disease or evidence of other diseases based upon a review of medical history that, in the opinion of the Investigator, would preclude safe subject participation in the study.
- Test articles are cost-prohibitive for subjects
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Collagenase Santyl
Applied topically (2 mm thickness once daily)
|
A sterile, enzymatic debriding agent which contains 250 collagenase units per gram of white petrolatum, United States Pharmacopeia (USP).
|
Sham Comparator: Bacitracin
Applied topically (2 mm thickness) once daily
|
One gram is equal to 500 bacitracin units; one unit of bacitracin is equivalent to 0.026 milligrams.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion Healed
Time Frame: 21 Days After Treatment
|
Outcome will be reported as percent of wound epithelialization.
|
21 Days After Treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Scar Appearance using the Vancouver Scar Scale
Time Frame: 90 Days After Treatment
|
Scar appearance will be documented using the Vancouver Scar Scale.
It assesses 4 variables: vascularity, height/thickness, pliability, and pigmentation.
|
90 Days After Treatment
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to Healing
Time Frame: Up To 90 Days After Treatment
|
Up To 90 Days After Treatment
|
Incidence of Burn Wound Infection
Time Frame: Up to 90 Days After Treatment
|
Up to 90 Days After Treatment
|
Collaborators and Investigators
Investigators
- Principal Investigator: Dhaval Bhavsar, MD, University of Kansas Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13663
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Burn, Partial Thickness
-
Amarantus BioScience Holdings, Inc.Amarex Clinical ResearchUnknownThermal Injury | Deep Partial-Thickness Burn | Full-Thickness BurnUnited States
-
Nanomedic Technologies Ltd.CompletedPartial Thickness BurnIsrael
-
Molnlycke Health Care ABRecruitingPartial-thickness BurnUnited States
-
University of TennesseeMedline IndustriesCompletedBurns | Partial-thickness BurnUnited States
-
KeraNetics, LLCUnited States Department of Defense; Wake Forest UniversityRecruitingPartial-thickness BurnUnited States
-
King Edward Medical UniversityUnknownPartial-thickness BurnPakistan
-
J. Peter Rubin, MDUnited States Department of Defense; Synedgen, Inc.Terminated
-
Chulalongkorn UniversityNational Science and Technology Development Agency, ThailandCompletedDeep Partial Thickness BurnThailand
-
GeneScience Pharmaceuticals Co., Ltd.Third Military Medical University; Shanghai Jiao Tong University School of... and other collaboratorsCompletedDeep Partial Thickness Burn
-
The University of Texas Medical Branch, GalvestonWithdrawnPartial-thickness BurnUnited States
Clinical Trials on Collagenase Santyl
-
HealthpointCompleted
-
Integra LifeSciences CorporationTerminated
-
HealthpointCompletedDiabetic Foot Ulcers | Diabetic Foot WoundsUnited States
-
HealthpointCompletedDiabetic Foot Ulcers | Diabetic Foot WoundsUnited States, Canada
-
University of MiamiCompletedDiabetic Foot | Foot UlcerUnited States
-
Stony Brook UniversityCompletedAdhesion of Flexor Tendon of HandUnited States
-
HealthpointCompletedFollow up to Acute Wound Scar StudyUnited States
-
HealthpointCompletedDiabetic Foot Ulcers | Foot WoundsUnited States
-
Smith & Nephew, Inc.WithdrawnPressure Ulcer | Foot Ulcer, DiabeticUnited States